Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Hard-to-Treat myeloma: first human trial of forimtamig begins

NCT ID NCT04557150

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called forimtamig in 225 people with multiple myeloma that had returned or stopped responding to standard treatments. The main goals were to check safety and find the right dose. Participants received the drug by IV or injection, and researchers monitored side effects and how the drug moved through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Forimtamig (RO7425781)
What this could lead to
If successful, this could lead to a new treatment option for people with multiple myeloma who have run out of standard therapies.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is not yet proven to work. Side effects and limited effectiveness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

  • CHRU Lille - Hôpital Claude Huriez

    Lille, 59037, France

  • CHU NANTES - Hôtel Dieu

    Nantes, 44093, France

  • Clinica Universitaria de Navarra

    Pamplona, Navarre, 31008, Spain

  • Fond. IRCCS Istituto Nazionale Tumori

    Milan, Lombardy, 20133, Italy

  • Hopital De Haut Leveque

    Pessac, 33604, France

  • Hospital Clinico Universitario de Salamanca

    Salamanca, 37007, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, Cantabria, 39008, Spain

  • IRCCS Istituto Nazionale dei Tumori di Napoli - Pascale Ematologia Oncologica

    Naples, Campania, 80131, Italy

  • Instituto Clinico Humanitas

    Rozzano, Lombardy, 20089, Italy

  • New Zealand Clinical Research - Auckland

    Auckland, 1010, New Zealand

  • Odense Universitetshospital

    Odense C, 5000, Denmark

  • Peter MacCallum Cancer Center

    Melbourne, Victoria, 3000, Australia

  • Policlinico S.Orsola-Malpighi

    Bologna, Emilia-Romagna, 40138, Italy

  • Rigshospitalet

    København Ø, 2100, Denmark

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Seoul St Mary's Hospital

    Seoul, 06591, South Korea

  • St James University Hospital

    Leeds, LS9 7TF, United Kingdom

  • UZ Gent

    Ghent, 9000, Belgium

  • University College London Hospitals NHS Foundation Trust

    London, W1T 7HA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.